Avinger (NASDAQ:AVGR) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR) in a research report report published on Thursday morning. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright restated a buy rating and set a $5.00 price objective on shares of Avinger in a report on Thursday, March 21st.

Avinger Trading Up 1.6 %

NASDAQ:AVGR traded up $0.06 during trading hours on Thursday, reaching $3.90. 10,223 shares of the company’s stock were exchanged, compared to its average volume of 13,949. Avinger has a 12 month low of $2.50 and a 12 month high of $18.00. The business’s 50-day simple moving average is $3.46 and its two-hundred day simple moving average is $3.28.

Avinger (NASDAQ:AVGR) last released its quarterly earnings data on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.52 million. On average, research analysts anticipate that Avinger will post -2.08 EPS for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.